Duodenal levodopa infusion in Parkinson's disease--long-term experience.
about
Available and emerging treatments for Parkinson's disease: a reviewThe hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyDevelopment of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedsideProblems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tabletsContinuous drug delivery in Parkinson's disease.Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Advances in the delivery of treatments for Parkinson's disease.Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series.Duodenal levodopa infusion for the treatment of Parkinson's disease.Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Current status of symptomatic medical therapy in Parkinson's diseaseSelecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based reviewApomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Therapeutic options for continuous dopaminergic stimulation in Parkinson's diseaseWhat is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?Therapies for dopaminergic-induced dyskinesias in Parkinson disease.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.Future treatments for Parkinson's disease: surfing the PD pipeline.Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.The role of subcutaneous infusion of apomorphine in Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy.Continuous levodopa for advanced Parkinson's disease.Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA.
P2860
Q24633444-B3709D34-A75C-426F-9CB7-E70CE4F4BBB7Q30248922-F2CB2C4D-197F-4821-A181-2EB46EB83E1FQ30366253-EB20B06F-BD9F-4BEA-B975-8DA88C2FF71CQ30852749-A395C0A9-E4F5-448C-B9D5-A5C0E2728311Q33917419-17839169-4484-40EA-884E-2D54EE39E3DCQ34209542-B6637BB9-1D24-44E2-B47D-F60976F41A1FQ34390800-69C64FCD-EAC8-46B0-964E-73A777FC67AEQ34604998-88109941-2E98-40FC-9017-AE9DB1C797B3Q35614156-37CDA6AF-8A01-4C27-8265-C5566856D7E1Q36316936-9B02BF11-E8E0-45B3-A6E6-8FAA49020930Q36641474-4088E08E-AD45-4A84-A081-F0B887E1A555Q36651313-810F2F59-2C75-4257-B6BE-079B41F156BDQ36765792-D4F6C3AF-CDA2-42AA-B560-02E71DC3CADDQ37086136-EFC501DF-A8C9-446F-AFE0-09CF0C34BBFFQ37115650-27043692-442F-43C2-B67B-57C2DC6B66ECQ37131229-CF94BD55-C653-4444-B27D-2069E21309E6Q37302240-8AEE80B8-86D1-432A-9943-8028E48EE795Q37507973-40AF54DE-1D0E-4DC4-B1F8-EAEFC060B0E3Q37698585-90FA9D00-72BE-4A2D-9E05-09DB0C04B413Q37823337-163E3B50-17A7-431D-A226-FBD9F6F89AC8Q37824279-831388C3-E88D-4FB8-839E-08849E90CFDBQ37890986-82E1C683-EA77-4F50-B041-4B97D73A3D8CQ37924626-604EDE9E-5CD4-4FE4-AE04-75A9D67688EAQ37950428-A4C895C6-DDDA-425A-9B1A-BA0DC5186BFCQ37955238-AA224CF5-EFB0-40F2-9AF9-C4862C01CED1Q38112219-6E49E22B-51BF-47E4-A4B5-B971DDE9BD51Q38215506-E745C72C-8FE4-4238-B73F-1D40970064F9Q38219351-3FC369F8-CAF1-467C-9377-C2A4FC3B6C7AQ38262418-FE06B369-26CC-4181-B8A2-6B7A28CE650BQ38478999-DDC07C55-7FDD-412F-A9F5-1F7B3668E0E3Q38530328-80D80C00-A75B-47B1-8A53-E1E301A734EBQ38742792-4A2571A9-ADA4-4D99-911E-2F50FB7C0287Q39746877-0FB7C6BA-9FF0-4CF2-B131-12700DF73E60Q39942155-3E150DB4-7AE1-4680-9BB8-8357F703C1D7Q40551791-7A048C8E-6BAE-4F72-91B0-70E498B7E53DQ40694060-B1A6BA18-EE5C-47F3-A5F1-D9FE656A6517Q40825490-A575A6E1-C08D-494B-BB2A-69EA9FA7AF10Q41825026-6BA873CE-6D8A-49EC-8C3B-A3420DAB34D7Q44187507-605A69F0-4B92-4428-AA50-86AED27676FFQ44384261-31C624F5-253A-4564-9247-434606B6C847
P2860
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@en
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@nl
type
label
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@en
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@nl
prefLabel
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@en
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@nl
P2093
P2860
P1476
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
@en
P2093
Aquilonius SM
P2860
P304
P356
10.1034/J.1600-0404.2001.00153.X
P407
P577
2001-12-01T00:00:00Z